In two recent studies (SURMOUNT-1 & STEP1) patients lost 17.8% on Tirzepatide versus 12.4% on Semaglutide more than placebo
The FDA approved tirzepatide for adults with a body mass index (BMI) of 30 kg/m or higher (obesity classification), or a BMI of 27 kg/m or higher with at least one weight-related condition such as hypertension, type 2 diabetes, or cardiovascular disease
When appetite drops and digestion slows, you naturally end up eating less overall, which makes it tougher to hit your daily protein intake
La dosis de mantenimiento de Wegovy puede cambiar cuando llegues a la fase de mantenimiento de peso
A complex interplay occurs between environmental (e.g., diet and medications) and host factors within the gastrointestinal tract, where symbiotic microorganisms reside
We schedule regular follow-up appointments to track your progress, adjust your treatment plan as needed, and offer in-clinic support and advice to help you reach your weight-loss goals safely and sustainably under expert supervision
